Therapeutic challenges for systemic sclerosis: facts and future targets

Area of Science:

• Cardiology
• Pulmonology
• Rheumatology

Background:

• Pulmonary arterial hypertension (PAH) is a significant cause of mortality in systemic sclerosis (SSc).
• Despite therapeutic advancements, early diagnosis and intervention remain critical for improving PAH prognosis.
• Pathogenic pathways like prostacyclin, endothelin, and nitric oxide signaling are key targets for PAH treatment.

Purpose of the Study:

• To review current and emerging therapies for pulmonary arterial hypertension (PAH).
• To highlight the importance of targeting specific pathogenic pathways in PAH management.
• To discuss the role of novel drugs in improving outcomes for PAH patients, including those with SSc.

Main Methods:

• Review of current literature on PAH therapies.
• Analysis of drugs targeting prostacyclin, endothelin, and nitric oxide pathways.
• Evaluation of treatment efficacy and administration routes for various PAH medications.

Main Results:

• Prostacyclin analogues (epoprostenol, iloprost, treprostinil, beraprost) have demonstrated efficacy in improving life expectancy and function.
• Endothelin receptor antagonists (bosentan, sitaxsentan, ambrisentan) improve exercise capacity and survival in PAH.
• Phosphodiesterase type 5 inhibitors (sildenafil, vardenafil, tadalafil) enhance hemodynamic parameters with minimal side effects.
• Combination therapy may offer maximal clinical benefit, potentially as initial PAH treatment.

Conclusions:

• Targeted therapies addressing prostacyclin, endothelin, and nitric oxide pathways have significantly advanced PAH management.
• Newer oral and inhaled medications offer improved administration options and efficacy.
• Combination therapies hold promise for optimizing treatment outcomes in pulmonary arterial hypertension.